Phase Ib/II study results indicate rilotumumab may be effective for treating gastric and oesophagogastric cancer expressing MET...
ESMO members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.
Welcome to OncologyPRO – educational and scientific content for ESMO members. To gain full access to all the resources on this website, you must be an ESMO member.
ESMO members: Please sign in using your myESMO username and password. To ensure a seamless browsing experience, we suggest that you sign in at the start of your visit.